84-3397-76　DARC (CT) (Duffy Antigen/Chemokine Receptor, Duffy Antigen/Chemokine Receptor, Fy Glycoprotein D, GpFy, Cell Adhesion Molecule 3, CADM3, Plasmodium Vivax Receptor,CCBP1, CD234, CD234 antigen, Dfy, GpFy, Plasmodium vivax receptor) (HRP) 100ul　D1065-50H-HRP

特徴

• CD234 is a non-specific receptor for a number of cytokines including IL-8, GRO, RANTES, MCP-1 and TARC.
• CD234 also functions as the receptor for the malaria parasites Plasmodium vivax and P.
• knowlesi.
• CD234 is also responsible for the Duffy blood group system where a substitution at position 42 of either Gly-42 or Asp-42 results in Fy(A) or Fy(B).
• CD234 is present in adult kidney, adult spleen, bone marrow and fetal liver.
• In particular, it is expressed along post capillary venules throughout the body, except in the adult liver.
• Erythroid cells and post capillary venule endothelium are the principle tissues expressing duffy.
• Fy(-A-B) individuals do not express duffy in the bone marrow, however they do, in postcapillary venule endothelium.
• It has been demonstrated that CD234 exists in multiple isoforms.
• Applications:Suitable for use in Western Blot and Immunohistochemistry.
• Other applications have not tested.
• Recommended Dilution:Immunohistochemistry: Paraffin.
• Requires antigen retrieval using heat treatment prior to staining paraffin sections.
• Sodium citrate buffer pH 6.0 is recommended.
• Optimal dilutions to be determined by the researcher.
• Immunohistochemistry Positive Control Tissue:Mouse brain
• Storage and Stability:Store product at 4°C if to be used immediately within two weeks.
• For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C.
• Aliquots are stable at -20°C for 12 months after receipt.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• Note: Sodium azide is a potent inhibitor of peroxidase and should not be added to HRP conjugates.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Note: Applications are based on unconjugated antibody.